Intellia Therapeutics (NTLA) Other Non-Current Liabilities (2015 - 2022)
Intellia Therapeutics (NTLA) reported Other Non-Current Liabilities of $24.0 million for Q4 2022, up 29.17% on a QoQ basis from $18.6 million in Q3 2022.
Intellia Therapeutics (NTLA) has 5 years of Other Non-Current Liabilities data on file, last reported at $24.0 million in Q4 2022.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $24.0 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $24.0 million (changed N/A YoY) and the FY2022 annual result came in at $24.0 million, changed N/A from the prior year.
- Other Non-Current Liabilities improved to $24.0 million in Q4 2022 per NTLA's latest filing, from $18.6 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $24.0 million in Q4 2022 and bottomed at $13000.0 in Q4 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 24.03 Mn |
| Sep 30, 2022 | 18.60 Mn |
| Jun 30, 2022 | 10.79 Mn |
| Mar 31, 2022 | 10.96 Mn |
| Dec 31, 2018 | 13,000.00 |
| Sep 30, 2018 | 52,000.00 |
| Jun 30, 2018 | 92,000.00 |
| Mar 31, 2018 | 131,000.00 |
| Dec 31, 2017 | 168,000.00 |
| Sep 30, 2017 | 201,000.00 |
| Jun 30, 2017 | 234,000.00 |
| Mar 31, 2017 | 378,000.00 |
| Dec 31, 2016 | 293,000.00 |
| Sep 30, 2016 | 306,000.00 |
| Jun 30, 2016 | 363,000.00 |
| Mar 31, 2016 | 349,000.00 |
| Dec 31, 2015 | 323,000.00 |